Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 356

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis

Open access
Windecker, S., Stortecky, S., Stefanini, G. G., daCosta, B. R., Rutjes, A. W., Di Nisio, M., Siletta, M. G., Maione, A., Alfonso, F., Clemmensen, P. M., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S., Kappetein, A. P., Kastrati, A., Knuuti, J., Landmesser, U., Laufer, G., Neumann, F.-J., Richter, D., Schauerte, P., Sousa Uva, M., Taggart, D. P., Torracca, L., Valgimigli, M., Wijns, W., Witkowski, A., Kolh, P., Juni, P.·2014·BMJ

Abstract

OBJECTIVE: To investigate whether revascularisation improves prognosis compared with medical treatment among patients with stable coronary artery disease. DESIGN: Bayesian network meta-analyses to combine direct within trial comparisons between treatments with indirect evidence from other trials while maintaining randomisation. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: A strategy of initial medical treatment compared with revascularisation by coronary artery bypass grafting or Food and Drug Administration approved techniques for percutaneous revascularization: balloon angioplasty, bare metal stent, early generation paclitaxel eluting stent, sirolimus eluting stent, and zotarolimus eluting (Endeavor) stent, and new generation everolimus eluting stent, and zotarolimus eluting (Resolute) stent among patients with stable coronary artery disease. DATA SOURCES: Medline and Embase from 1980 to 2013 for randomised trials comparing medical treatment with revascularisation. MAIN OUTCOME MEASURE: All cause mortality. RESULTS: 100 trials in 93,553 patients with 262,090 patient years of follow-up were included. Coronary artery bypass grafting was associated with a survival benefit (rate ratio 0.80, 95% credibility interval 0.70 to 0.91) compared with medical treatment. New generation drug eluting stents (everolimus: 0.75, 0.59 to 0.96; zotarolimus (Resolute): 0.65, 0.42 to 1.00) but not balloon angioplasty (0.85, 0.68 to 1.04), bare metal stents (0.92, 0.79 to 1.05), or early generation drug eluting stents (paclitaxel: 0.92, 0.75 to 1.12; sirolimus: 0.91, 0.75 to 1.10; zotarolimus (Endeavor): 0.88, 0.69 to 1.10) were associated with improved survival compared with medical treatment. Coronary artery bypass grafting reduced the risk of myocardial infarction compared with medical treatment (0.79, 0.63 to 0.99), and everolimus eluting stents showed a trend towards a reduced risk of myocardial infarction (0.75, 0.55 to 1.01). The risk of subsequent revascularisation was noticeably reduced by coronary artery bypass grafting (0.16, 0.13 to 0.20) followed by new generation drug eluting stents (zotarolimus (Resolute): 0.26, 0.17 to 0.40; everolimus: 0.27, 0.21 to 0.35), early generation drug eluting stents (zotarolimus (Endeavor): 0.37, 0.28 to 0.50; sirolimus: 0.29, 0.24 to 0.36; paclitaxel: 0.44, 0.35 to 0.54), and bare metal stents (0.69, 0.59 to 0.81) compared with medical treatment. CONCLUSION: Among patients with stable coronary artery disease, coronary artery bypass grafting reduces the risk of death, myocardial infarction, and subsequent revascularisation compared with medical treatment. All stent based coronary revascularisation technologies reduce the need for revascularisation to a variable degree. Our results provide evidence for improved survival with new generation drug eluting stents but no other percutaneous revascularisation technology compared with medical treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.g3859

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 356

Metadata

Authors
Windecker, S., Stortecky, S., Stefanini, G. G., daCosta, B. R., Rutjes, A. W., Di Nisio, M., Siletta, M. G., Maione, A., Alfonso, F., Clemmensen, P. M., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S., Kappetein, A. P., Kastrati, A., Knuuti, J., Landmesser, U., Laufer, G., Neumann, F.-J., Richter, D., Schauerte, P., Sousa Uva, M., Taggart, D. P., Torracca, L., Valgimigli, M., Wijns, W., Witkowski, A., Kolh, P., & Juni, P.
Venue
BMJ
Publisher
BMJ
Published
2014-06-23
Volume
348
Issue
jun23 8
Pages
g3859-g3859
ISSN
1756-1833 (ISSN-L)
OpenAlex
W2064409947
Cited by
356
References
55
FWCI
41.22
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. https://app.cochat.ai/papers/10.1136/bmj.g3859
The paper
Windecker, S., Stortecky, S., Stefanini, G. G., daCosta, B. R., Rutjes, A. W., Di Nisio, M., Siletta, M. G., Maione, A., Alfonso, F., Clemmensen, P. M., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S., Kappetein, A. P., Kastrati, A., Knuuti, J., . . . Juni, P. (2014). Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. https://doi.org/10.1136/bmj.g3859

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.